How Gilead deal positions Galapagos to become Europe’s next big biotech

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow.

The July 14 deal not only provides Galapagos N.V. with over $5 billion for R&D expansion or strategic acquisitions, it’s also structured to ensure that neither partner Gilead Sciences Inc., nor any other company, can acquire the Belgian biotech over the next 10 years...